3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Stomach Neoplasms
7
Rectal Neoplasms
5
Colorectal Neoplasms
5
Colonic Neoplasms
3
Neoplasm Metastasis
2
Gastrointestinal Neoplasms
2
Recurrence
1
Rcctal Cancer
1
Neoplasms
1
Metastatic HER2 Positive Gastroesophageal Junction Cancer
1
HER2-positive Locally Advanced Resectable Gastric Cancer
1
Gastrointestinal Diseases
1
Gastric Adenocarcinoma
1
Digestive System Diseases
1
Carcinoma
1
Adenocarcinoma
1
Adebrelimab (SHR-1316)
1
Interventions
pembrolizumab
47
Specimen Handling
29
Magnetic Resonance Spectroscopy
25
Biopsy
25
Radiosurgery
17
Gemcitabine
17
Nivolumab
15
Paclitaxel
14
Cyclophosphamide
13
Cisplatin
13
Carboplatin
13
Bevacizumab
12
Drug Therapy
11
Taxes
10
Radiotherapy
10
Oxaliplatin
10
Leucovorin
10
Irinotecan
10
Fluorouracil
10
Capecitabine
10
trastuzumab deruxtecan
8
fludarabine
8
Pemetrexed
8
Doxorubicin
8
Cetuximab
8
cemiplimab
7
abemaciclib
7
Trastuzumab
7
Fulvestrant
7
Docetaxel
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm Metastasis
×
XELOX
×
Clear all
NCT06475352
2026-04-23
FUDOSE
UNICANCER
Phase 2
Recruiting
400 enrolled
NCT06346197
2026-04-21
CIME
Centre Leon Berard
Phase 3
Recruiting
132 enrolled